tradingkey.logo

Twist Bioscience Corp

TWST
33.050USD
-0.530-1.58%
收盘 12/26, 16:00美东报价延迟15分钟
2.00B总市值
亏损市盈率 TTM

Twist Bioscience Corp

33.050
-0.530-1.58%

关于 Twist Bioscience Corp 公司

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Twist Bioscience Corp简介

公司代码TWST
公司名称Twist Bioscience Corp
上市日期Oct 31, 2018
CEOLeproust (Emily M)
员工数量979
证券类型Ordinary Share
年结日Oct 31
公司地址681 Gateway Blvd.
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94080
电话18007190671
网址https://www.twistbioscience.com/
公司代码TWST
上市日期Oct 31, 2018
CEOLeproust (Emily M)

Twist Bioscience Corp公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
571.81K
-0.39%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
208.77K
+44.42%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
90.42K
-0.44%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
86.38K
-1.01%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
47.19K
+205.88%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
22.25K
+25.16%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
15.81K
+39.44%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
5.55K
-55.92%
Mr. Robert Werner
Mr. Robert Werner
Chief Accounting Officer, Vice President
Chief Accounting Officer, Vice President
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
571.81K
-0.39%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
208.77K
+44.42%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
92.71K
+5.07%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
90.42K
-0.44%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
86.38K
-1.01%
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
47.19K
+205.88%

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%
地区USD
名称
营收
占比
Americas
59.39M
61.82%
EMEA
30.74M
32.00%
APAC
5.93M
6.17%
业务
地区
业务USD
名称
营收
占比
NGS tools
55.28M
57.55%
Synthetic genes
27.68M
28.82%
Antibody discovery
5.61M
5.84%
Oligo pools
5.42M
5.65%
DNA libraries
2.06M
2.14%

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
其他
54.46%
持股股东
持股股东
占比
ARK Investment Management LLC
11.00%
Artisan Partners Limited Partnership
10.48%
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
7.87%
William Blair Investment Management, LLC
6.77%
其他
54.46%
股东类型
持股股东
占比
Investment Advisor
66.18%
Investment Advisor/Hedge Fund
36.08%
Hedge Fund
9.93%
Research Firm
5.45%
Individual Investor
2.69%
Pension Fund
1.58%
Bank and Trust
0.55%
Family Office
0.17%
Insurance Company
0.07%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
566
71.88M
119.09%
+752.75K
2025Q2
575
70.44M
116.72%
-302.44K
2025Q1
585
70.23M
117.22%
-1.63M
2024Q4
578
67.47M
113.11%
-8.03M
2024Q3
588
67.80M
115.74%
-8.48M
2024Q2
579
66.59M
114.39%
-10.53M
2024Q1
565
68.18M
117.94%
-8.61M
2023Q4
559
67.81M
117.39%
-11.70M
2023Q3
560
68.09M
118.66%
-11.36M
2023Q2
577
69.42M
121.49%
-5.07M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
ARK Investment Management LLC
6.40M
10.6%
+158.85K
+2.54%
Jun 30, 2025
Artisan Partners Limited Partnership
6.41M
10.62%
+1.35M
+26.67%
Sep 30, 2025
The Vanguard Group, Inc.
5.82M
9.64%
-36.15K
-0.62%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.86M
8.05%
+226.25K
+4.89%
Jun 30, 2025
William Blair Investment Management, LLC
3.91M
6.47%
+99.74K
+2.62%
Jun 30, 2025
EdgePoint Investment Group Inc.
2.39M
3.95%
+1.27M
+114.33%
Jun 30, 2025
State Street Investment Management (US)
2.50M
4.14%
-192.68K
-7.15%
Jun 30, 2025
Amova Asset Management Co., Ltd.
2.30M
3.81%
-116.36K
-4.82%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
ARK Genomic Revolution ETF
6.24%
iShares Genomics Immunology and Healthcare ETF
3.92%
Global X Genomics & Biotechnology ETF
2.09%
ROBO Global Healthcare Technology & Innovation ETF
2%
WisdomTree BioRevolution Fund
1.79%
ARK Innovation ETF
1.47%
Franklin Genomic Advancements ETF
1.17%
State Street SPDR S&P Biotech ETF
0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.66%
Direxion Daily S&P Biotech Bull 3X Shares
0.56%
查看更多
ARK Genomic Revolution ETF
占比6.24%
iShares Genomics Immunology and Healthcare ETF
占比3.92%
Global X Genomics & Biotechnology ETF
占比2.09%
ROBO Global Healthcare Technology & Innovation ETF
占比2%
WisdomTree BioRevolution Fund
占比1.79%
ARK Innovation ETF
占比1.47%
Franklin Genomic Advancements ETF
占比1.17%
State Street SPDR S&P Biotech ETF
占比0.92%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比0.66%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.56%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Twist Bioscience Corp的前五大股东是谁?

Twist Bioscience Corp 的前五大股东如下:
ARK Investment Management LLC持有股份:6.40M,占总股份比例:10.60%。
Artisan Partners Limited Partnership持有股份:6.41M,占总股份比例:10.62%。
The Vanguard Group, Inc.持有股份:5.82M,占总股份比例:9.64%。
BlackRock Institutional Trust Company, N.A.持有股份:4.86M,占总股份比例:8.05%。
William Blair Investment Management, LLC持有股份:3.91M,占总股份比例:6.47%。

Twist Bioscience Corp的前三大股东类型是什么?

Twist Bioscience Corp 的前三大股东类型分别是:
ARK Investment Management LLC
Artisan Partners Limited Partnership
The Vanguard Group, Inc.

有多少机构持有Twist Bioscience Corp(TWST)的股份?

截至2025Q3,共有566家机构持有Twist Bioscience Corp的股份,合计持有的股份价值约为71.88M,占公司总股份的119.09%。与2025Q2相比,机构持股有所增加,增幅为2.37%。

哪个业务部门对Twist Bioscience Corp的收入贡献最大?

在FY2025Q3,NGS tools业务部门对Twist Bioscience Corp的收入贡献最大,创收55.28M,占总收入的57.55%。
KeyAI